secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2026-07-29T20:10:17+00:00
Accession:  0001193125-26-323729
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M
----------------------------------------------------------------------------

- Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).
- GAAP net loss $18.4M ($0.31/sh); non-GAAP net loss $8.3M ($0.14/sh), improved from $19.7M loss a year ago.
- Gross margin 82% (non-GAAP 85%), up from 78% (83%) YoY.
- Raised 2026 net sales guidance to $680-700M from prior $620-635M.
- Cash $289.3M, no debt; cites iDose TR and Epioxa as growth drivers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/0001193125-26-323729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/gkos-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-323729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer